Are there any upcoming catalysts or earnings releases that could further influence the stock after this compliance announcement?

Upcoming catalysts

Beyond the compliance‑re‑gain announcement, the next material driver for TRIB will be its quarterly earnings. The company reports on a calendar‑quarter basis and, given the September 2 filing, the most immediate filing deadline is the Q3 2025 earnings release, which the company typically files in early‑mid November. The earnings call will be the first opportunity for management to update investors on the performance of its flagship diabetes‑management platform, the progress of its wearable biosensor pipeline, and any new partnership or licensing agreements. Analysts will also be looking for guidance on the Q4 2025 outlook, especially any expected revenue contribution from the recently launched TRIB‑DX point‑of‑care panels.

A secondary catalyst could come from regulatory or commercial milestones. Trinity Biotech has several FDA and EU‑CE marked submissions in its pipeline (e.g., the next‑generation continuous glucose monitor and a new infectious‑disease assay). Any positive FDA advisory‑committee feedback, clearance, or market‑launch announcement in the next 6‑12 weeks would likely add a fresh upward bias to the stock. The company also tends to present data at major conferences (AACC, ADA, MedTech) in the fall; a positive abstract or poster could act as a short‑term price spark.

Trading implications

• Short‑term: The compliance win removed the immediate downside risk of delisting, and the stock is now trading above the $1.00 threshold. Technicals show the price holding near the $1.20‑$1.30 range with modest upside momentum. A pull‑back toward the 20‑day EMA (~$1.15) could present a buying opportunity, provided volume supports the move.
• Medium‑term: Keep the November earnings date on the calendar. If pre‑earnings sentiment is positive (e.g., strong order backlog, favorable regulatory updates), a position could be built now with a tight stop just below the $1.10 support. Conversely, a miss on earnings or lack of catalyst news could test the $1.00 floor, at which point the risk of a renewed compliance issue would re‑emerge.
• Actionable: Monitor Nasdaq filings (Form 8‑K) for any press releases on FDA clearances, partnership agreements, or conference abstracts over the next 4‑8 weeks. If such news materializes, consider adding on pull‑backs; if the earnings date approaches without additional catalyst, maintain a watch‑list stance and be ready to adjust stops based on the post‑earnings reaction.